Insider Selling: Tactile Systems Technology, Inc. (NASDAQ:TCMD) VP Sells 815 Shares of Stock

Tactile Systems Technology, Inc. (NASDAQ:TCMD) VP Kristie Burns sold 815 shares of the firm’s stock in a transaction on Monday, May 6th. The shares were sold at an average price of $14.37, for a total value of $11,711.55. Following the sale, the vice president now directly owns 62,574 shares of the company’s stock, valued at approximately $899,188.38. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Kristie Burns also recently made the following trade(s):

• On Thursday, February 29th, Kristie Burns sold 243 shares of Tactile Systems Technology stock. The shares were sold at an average price of $15.25, for a total value of $3,705.75.
• On Monday, February 26th, Kristie Burns sold 2,015 shares of Tactile Systems Technology stock. The shares were sold at an average price of $15.90, for a total value of $32,038.50.
• On Friday, February 23rd, Kristie Burns sold 2,249 shares of Tactile Systems Technology stock. The shares were sold at an average price of $14.80, for a total value of $33,285.20.

Tactile Systems Technology Stock Performance

TCMD stock traded down $0.59 during trading hours on Wednesday, hitting $13.85. 370,018 shares of the stock were exchanged, compared to its average volume of 277,495. The company has a current ratio of 3.54, a quick ratio of 2.99 and a debt-to-equity ratio of 0.14. Tactile Systems Technology, Inc. has a 12 month low of $9.69 and a 12 month high of $26.11. The firm has a market capitalization of $329.08 million, a P/E ratio of 11.54 and a beta of 1.23. The company has a 50-day simple moving average of $15.21 and a two-hundred day simple moving average of $14.19.

Tactile Systems Technology (NASDAQ:TCMD) last released its earnings results on Tuesday, February 20th. The company reported $0.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.13 by $0.25. Tactile Systems Technology had a return on equity of 17.08% and a net margin of 10.39%. The firm had revenue of $77.65 million for the quarter, compared to analysts’ expectations of $78.85 million. During the same quarter in the previous year, the business posted $0.29 earnings per share. On average, analysts forecast that Tactile Systems Technology, Inc. will post 0.56 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Tactile Systems Technology

Several institutional investors have recently bought and sold shares of TCMD. Bank of New York Mellon Corp increased its holdings in shares of Tactile Systems Technology by 6.9% in the third quarter. Bank of New York Mellon Corp now owns 126,314 shares of the company’s stock worth $1,775,000 after buying an additional 8,113 shares during the period. New York State Teachers Retirement System purchased a new position in Tactile Systems Technology during the 3rd quarter valued at about $29,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Tactile Systems Technology during the 3rd quarter valued at about $80,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in Tactile Systems Technology during the 3rd quarter valued at about $237,000. Finally, Inspire Investing LLC purchased a new position in Tactile Systems Technology during the 3rd quarter valued at about $672,000. Hedge funds and other institutional investors own 83.43% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised Tactile Systems Technology from a “buy” rating to a “strong-buy” rating in a report on Tuesday.

About Tactile Systems Technology

Tactile Systems Technology, Inc, a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema in the home setting; and Entre Plus System, a portable pneumatic compression device for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers.